The presenilins in Alzheimer's disease--proteolysis holds the key
- PMID: 10542139
- DOI: 10.1126/science.286.5441.916
The presenilins in Alzheimer's disease--proteolysis holds the key
Abstract
Alzheimer's disease (AD) research has shown that patients with an inherited form of the disease carry mutations in the presenilin proteins or the amyloid precursor protein (APP). These disease-linked mutations result in increased production of the longer form of amyloid-beta (the primary component of the amyloid deposits found in AD brains). However, it is not clear how the presenilins contribute to this increase. New findings now show that the presenilins affect APP processing through their effects on gamma-secretase, an enzyme that cleaves APP. Also, it is known that the presenilins are involved in the cleavage of the Notch receptor, hinting that they either directly regulate gamma-secretase activity or themselves are protease enzymes. These findings suggest that the presenilins may prove to be valuable molecular targets for the development of drugs to combat AD.
Similar articles
-
Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1.Nat Cell Biol. 2000 Jul;2(7):428-34. doi: 10.1038/35017062. Nat Cell Biol. 2000. PMID: 10878808
-
gamma-Secretase inhibitors as molecular probes of presenilin function.J Mol Neurosci. 2001 Oct;17(2):199-204. doi: 10.1385/JMN:17:2:199. J Mol Neurosci. 2001. PMID: 11816793 Review.
-
Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate Notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals.J Neurosci. 2003 Apr 15;23(8):3272-7. doi: 10.1523/JNEUROSCI.23-08-03272.2003. J Neurosci. 2003. PMID: 12716934 Free PMC article.
-
APP, Notch, and presenilin: molecular pieces in the puzzle of Alzheimer's disease.Int Immunopharmacol. 2002 Dec;2(13-14):1919-29. doi: 10.1016/s1567-5769(02)00179-0. Int Immunopharmacol. 2002. PMID: 12489805 Review.
-
Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease.Biochemistry. 1999 Aug 31;38(35):11223-30. doi: 10.1021/bi991080q. Biochemistry. 1999. PMID: 10471271 Review.
Cited by
-
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease.Alzheimers Res Ther. 2024 Jul 5;16(1):151. doi: 10.1186/s13195-024-01490-z. Alzheimers Res Ther. 2024. PMID: 38970127 Free PMC article. Clinical Trial.
-
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's Disease.medRxiv [Preprint]. 2024 Mar 22:2024.03.20.24304638. doi: 10.1101/2024.03.20.24304638. medRxiv. 2024. Update in: Alzheimers Res Ther. 2024 Jul 5;16(1):151. doi: 10.1186/s13195-024-01490-z PMID: 38562783 Free PMC article. Updated. Preprint.
-
The Potential of a Stratified Approach to Drug Repurposing in Alzheimer's Disease.Biomolecules. 2023 Dec 21;14(1):11. doi: 10.3390/biom14010011. Biomolecules. 2023. PMID: 38275752 Free PMC article. Review.
-
Application of N-Terminal Labeling Methods Provide Novel Insights into Endoproteolysis of the Prion Protein in Vivo.ACS Chem Neurosci. 2024 Jan 3;15(1):134-146. doi: 10.1021/acschemneuro.3c00533. Epub 2023 Dec 14. ACS Chem Neurosci. 2024. PMID: 38095594
-
Ginkgo Biloba and Long COVID: In Vivo and In Vitro Models for the Evaluation of Nanotherapeutic Efficacy.Pharmaceutics. 2023 May 22;15(5):1562. doi: 10.3390/pharmaceutics15051562. Pharmaceutics. 2023. PMID: 37242804 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
